We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
Read MoreHide Full Article
Key Takeaways
CNMD trades at 10.7X forward earnings, below its sub-industry, Medical sector and five-year median.
CONMED raised 2026 adjusted EPS guidance to $4.48-$4.60 as its remaining portfolio posts healthier growth.
Higher interest expense, lower free cash flow and unfinished supply-chain work constrain CNMD's upside.
CONMED Corporation (CNMD - Free Report) presents investors with a clear trade-off. The stock’s valuation is inexpensive relative to key benchmarks, while operating trends and the 2026 earnings outlook have improved.
The offset is execution risk. Cash flow, supply-chain work and higher financing costs still leave limited room for missteps, making the buy-versus-wait decision less straightforward.
CNMD Trades Below Key Valuation Benchmarks
CNMD trades at 10.82X forward 12-month earnings, below 17.71X for its Zacks sub-industry and 21.07X for the broader Zacks Medical sector. The current multiple is also well below the stock’s five-year median of 18.49X, underscoring the valuation discount.
Image Source: Zacks Investment Research
Stryker Corporation (SYK - Free Report) is a useful medtech reference because its portfolio spans MedSurg and Orthopaedics. Medtronic plc (MDT - Free Report) also provides relevant context through its surgical robotics and other surgical technology offerings. CNMD’s discount may attract value-oriented investors, but valuation alone does not resolve its company-specific execution risks.
CONMED’s Earnings Outlook Has Improved
Management raised 2026 adjusted earnings guidance to $4.48-$4.60 per share from $4.30-$4.45 after better-than-expected second-quarter results. The higher range reflects a lower expected earnings headwind from the gastroenterology exit and a larger contribution from share repurchases.
Those benefits are partly offset by higher interest expense and a higher tax-rate assumption. The revised outlook still marks a better earnings setup than management projected earlier in the year.
CNMD’s Portfolio Focus Supports Cleaner Growth
CONMED completed its gastroenterology exit in the second quarter, sharpening its focus on minimally invasive surgery, smoke evacuation and orthopedic soft-tissue repair. That leaves AirSeal, Buffalo Filter and BioBrace at the center of the company’s growth strategy.
Second-quarter organic constant-currency revenues excluding gastroenterology increased 6%, even though total constant-currency revenues declined 0.5%. The gap shows how the divestiture is still distorting reported growth while the remaining portfolio is expanding at a healthier pace.
CONMED Still Has Little Room for Execution Errors
Supply-chain conditions have improved, with service levels strengthening and backorders at multi-year lows, but the transformation is not finished. Inventories rose to $360.2 million at June 30 from $355.5 million at year-end as CONMED built supply to reduce stock-out risk.
Financing and cash-flow pressure add another constraint. Expected 2026 adjusted interest expense increased to about $33 million from $25-$27 million, while free cash flow guidance fell to about $115 million from roughly $125 million. Original equipment manufacturer smoke demand can also create quarterly volatility.
The valuation case is stronger than the near-term growth signal, but that does not make CNMD an automatic buy. Improving earnings, cleaner portfolio exposure and organic growth support the case for holding or selective accumulation, while execution and cash conversion argue for patience.
CNMD currently carries a Zacks Rank #3 (Hold). It also has a Value Score of A, Growth Score of C, Momentum Score of C and VGM Score of B. The Value Score highlights relative valuation appeal, while the Growth and Momentum scores are more neutral. Likewise, Stryker and Medtronic also carry a Zacks Rank of 3. With a Zacks Rank #3, the combined signals favor a balanced stance rather than a decisive buy call. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
Key Takeaways
CONMED Corporation (CNMD - Free Report) presents investors with a clear trade-off. The stock’s valuation is inexpensive relative to key benchmarks, while operating trends and the 2026 earnings outlook have improved.
The offset is execution risk. Cash flow, supply-chain work and higher financing costs still leave limited room for missteps, making the buy-versus-wait decision less straightforward.
CNMD Trades Below Key Valuation Benchmarks
CNMD trades at 10.82X forward 12-month earnings, below 17.71X for its Zacks sub-industry and 21.07X for the broader Zacks Medical sector. The current multiple is also well below the stock’s five-year median of 18.49X, underscoring the valuation discount.
Image Source: Zacks Investment Research
Stryker Corporation (SYK - Free Report) is a useful medtech reference because its portfolio spans MedSurg and Orthopaedics. Medtronic plc (MDT - Free Report) also provides relevant context through its surgical robotics and other surgical technology offerings. CNMD’s discount may attract value-oriented investors, but valuation alone does not resolve its company-specific execution risks.
CONMED’s Earnings Outlook Has Improved
Management raised 2026 adjusted earnings guidance to $4.48-$4.60 per share from $4.30-$4.45 after better-than-expected second-quarter results. The higher range reflects a lower expected earnings headwind from the gastroenterology exit and a larger contribution from share repurchases.
Those benefits are partly offset by higher interest expense and a higher tax-rate assumption. The revised outlook still marks a better earnings setup than management projected earlier in the year.
CNMD’s Portfolio Focus Supports Cleaner Growth
CONMED completed its gastroenterology exit in the second quarter, sharpening its focus on minimally invasive surgery, smoke evacuation and orthopedic soft-tissue repair. That leaves AirSeal, Buffalo Filter and BioBrace at the center of the company’s growth strategy.
Second-quarter organic constant-currency revenues excluding gastroenterology increased 6%, even though total constant-currency revenues declined 0.5%. The gap shows how the divestiture is still distorting reported growth while the remaining portfolio is expanding at a healthier pace.
CONMED Still Has Little Room for Execution Errors
Supply-chain conditions have improved, with service levels strengthening and backorders at multi-year lows, but the transformation is not finished. Inventories rose to $360.2 million at June 30 from $355.5 million at year-end as CONMED built supply to reduce stock-out risk.
Financing and cash-flow pressure add another constraint. Expected 2026 adjusted interest expense increased to about $33 million from $25-$27 million, while free cash flow guidance fell to about $115 million from roughly $125 million. Original equipment manufacturer smoke demand can also create quarterly volatility.
CONMED Corporation PEG Ratio (TTM)
CONMED Corporation peg-ratio-ttm | CONMED Corporation Quote
CNMD’s Value Signal Outweighs Its Growth Scores
The valuation case is stronger than the near-term growth signal, but that does not make CNMD an automatic buy. Improving earnings, cleaner portfolio exposure and organic growth support the case for holding or selective accumulation, while execution and cash conversion argue for patience.
CNMD currently carries a Zacks Rank #3 (Hold). It also has a Value Score of A, Growth Score of C, Momentum Score of C and VGM Score of B. The Value Score highlights relative valuation appeal, while the Growth and Momentum scores are more neutral. Likewise, Stryker and Medtronic also carry a Zacks Rank of 3. With a Zacks Rank #3, the combined signals favor a balanced stance rather than a decisive buy call. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.